We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 12, 2019

Early Induction Intensification With Cladribine, Cytarabine, and Mitoxantrone in AML Patients Treated With the DAC Induction

Leukemia and Lymphoma

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia and Lymphoma
Early Induction Intensification With Cladribine, Cytarabine, and Mitoxantrone (CLAM) in AML Patients Treated With the DAC Induction Regimen: A Prospective, Non-Randomized, Phase II Study of the Polish Adult Leukemia Group (PALG)
Leukemia and Lymphoma 2019 Oct 29;[EPub Ahead of Print], A Pluta, T Robak, K Brzozowski, K Stepka, E Wawrzyniak, A Krawczynska, M Czemerska, A Szmigielska-Kaplon, O Grzybowska-Izydorczyk, M Nowicki, P Stelmach, M Kuydowicz, T Gromek, M Hus, G Helbig, S Grosicki, E Bodzenta, M Razny, K Wojcik, L Bolkun, J Kloczko, W Knopinska-Posluszny, A Piekarska, A Hellman, M Sobas, T Wrobel, E Patkowska, E Lech-Maranda, K Warzocha, J Holowiecki, S Giebel, A Wierzbowska

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading